{"schema_version":"secwatch.filing_event.v1","accession":"0001401914-26-000025","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2026-05-14T20:01:25+00:00","discovered_at":"2026-05-14T20:03:31.375398+00:00","generated_at":"2026-05-14T21:02:56.894966+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Daré Bioscience reports Q1 2026 cash $18.5M; first product revenue expected June 2026","bullets":["Cash and equivalents $18.5M as of March 31; working capital ~$0.5M; revenue $0.2M from Gates Foundation services.","Ovaprene Phase 3 trial receives second positive DSMB review; enrollment expected to complete in 2026 with 2027 primary endpoint analysis.","DARE to PLAY sildenafil cream dispensing to commence summer 2026; pre-fulfillment prescribing active in all 50 states.","Flora Sync LF5 commercial launch in June 2026; first-ever product revenue milestone expected that month.","DARE-HPV Phase 2 study starting May 2026 with ARPA-H funding; DARE to RECLAIM targeting 2027 dispensing."],"urls":{"canonical":"https://secwatch.observer/filing/0001401914-26-000025","json":"https://secwatch.observer/filing/0001401914-26-000025.json","markdown":"https://secwatch.observer/filing/0001401914-26-000025.md","text":"https://secwatch.observer/filing/0001401914-26-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000025/0001401914-26-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000025/dare-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:02:56.894966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4203f0440596fb16037b25cd4764341bae664e5d","claim":"Dare Bioscience, Inc. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"On May 14, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026, a copy of which is furnished as Exhibit 99.1 to this report.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191426000025/0001401914-26-000025-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}